| Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy M Di Nisio, E Porreca, M Candeloro, M De Tursi, I Russi, AWS Rutjes Cochrane Database of Systematic Reviews, 2016 | 343 | 2016 |
| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 335 | 2019 |
| Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study N van Es, M Di Nisio, G Cesarman, A Kleinjan, HM Otten, I Mahé, IT Wilts, ... haematologica 102 (9), 1494, 2017 | 220 | 2017 |
| Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients A Marchetti, JF Palma, L Felicioni, TM De Pas, R Chiari, ... Journal of Thoracic Oncology 10 (10), 1437-1443, 2015 | 194 | 2015 |
| Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice A Cortellini, M Tucci, V Adamo, LS Stucci, A Russo, ET Tanda, ... Journal for immunotherapy of cancer 8 (2), 2020 | 159 | 2020 |
| Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in … V Graziano, A Grassadonia, L Iezzi, P Vici, L Pizzuti, M Barba, A Quinzii, ... The Breast 44, 33-38, 2019 | 155 | 2019 |
| Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: a real‐world transverse study A Cortellini, S Buti, D Santini, F Perrone, R Giusti, M Tiseo, M Bersanelli, ... The oncologist 24 (6), e327-e337, 2019 | 153 | 2019 |
| Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients A Cortellini, R Chiari, B Ricciuti, G Metro, F Perrone, M Tiseo, M Bersanelli, ... Clinical lung cancer 20 (4), 237-247. e1, 2019 | 136 | 2019 |
| Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy M Di Nisio, N Ferrante, M De Tursi, S Iacobelli, F Cuccurullo, HR Büller, ... Thrombosis and haemostasis 104 (11), 1049-1054, 2010 | 123 | 2010 |
| Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death … A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ... European Journal of Cancer 128, 17-26, 2020 | 95 | 2020 |
| Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: a systematic review and meta-analysis of phase III randomized clinical … A Grassadonia, I Sperduti, P Vici, L Iezzi, D Brocco, T Gamucci, L Pizzuti, ... Journal of Clinical Medicine 7 (12), 542, 2018 | 87 | 2018 |
| Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and … S Buti, M Bersanelli, F Perrone, M Tiseo, M Tucci, V Adamo, LS Stucci, ... European Journal of Cancer 142, 18-28, 2021 | 86 | 2021 |
| Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial S De Placido, C Gallo, M De Laurentiis, G Bisagni, G Arpino, MG Sarobba, ... The Lancet Oncology 19 (4), 474-485, 2018 | 84 | 2018 |
| Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study A Cortellini, F Bozzetti, P Palumbo, D Brocco, P Di Marino, N Tinari, ... Scientific reports 10 (1), 1456, 2020 | 77 | 2020 |
| Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 75 | 2020 |
| Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50% A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ... Cancer Immunology, Immunotherapy 69, 2209-2221, 2020 | 69 | 2020 |
| Arterial thrombosis in ambulatory cancer patients treated with chemotherapy M Di Nisio, N Ferrante, B Feragalli, M De Tursi, S Iacobelli, F Cuccurullo, ... Thrombosis research 127 (4), 382-383, 2011 | 59 | 2011 |
| Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study O Nigro, G Pinotti, F De Galitiis, FR Di Pietro, R Giusti, M Filetti, ... European Journal of Cancer 134, 19-28, 2020 | 53 | 2020 |
| Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells S Veschi, L De Lellis, R Florio, P Lanuti, A Massucci, N Tinari, M De Tursi, ... Journal of Experimental & Clinical Cancer Research 37, 1-13, 2018 | 53 | 2018 |
| Influenza vaccine indication during therapy with immune checkpoint inhibitors: a transversal challenge. The INVIDIa study M Bersanelli, D Giannarelli, P Castrignanò, G Fornarini, S Panni, ... Immunotherapy 10 (14), 1229-1239, 2018 | 50 | 2018 |
Clara NatoliDepartment of Medical, Oral and Biotechnological Sciences and CeSI-MeT University G. D'AnnunzioEmail verificata su unich.it
